RxDoctor Payments Data

McKenna Urey

Registered Nurse · Frederick, MDNPI 1831827070

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.

$421in general payments, 2019–2025

Across 21 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$64
  • Actelion Pharmaceuticals US, Inc.$59
  • Novo Nordisk$53
  • Novartis$43
  • Silk Road Medical, Inc.$43
  • AbbVie$36
  • plus $122 from 5 others

What the payments were for

  • Food & beverage$421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421 in reported general payments places this provider in the 80th percentile of 89 registered nurse providers in Maryland.

See all registered nurse providers in Maryland

Medicare billing

Part B allowed, 2024
$16,441
Medicare patients
158
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$14,093
Rosuvastatin Calcium36$815
Atorvastatin Calcium44$446
Metoprolol Succinate24$420
Lisinopril31$372
Losartan Potassium27$349
Amlodipine Besylate65$314
Levothyroxine Sodium29$264
Metformin Hcl14$206
Metformin Hcl ErMetformin Hcl11$159
Atenolol11$134
Metoprolol Tartrate35$119
Carvedilol15$86
Hydrochlorothiazide17$69
Hydralazine Hcl11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$14,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 registered nurse providers in Maryland.

Other registered nurse in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →